Left-sided pancreatic cancer - tumors arising in the body or tail of the pancreas - accounts for roughly 20–30% of all pancreatic ductal adenocarcinoma cases. Unlike head tumors that cause early biliary obstruction, body/tail cancers are often diagnosed late, compounding the challenge of achieving curative resection.
Standard surgical treatment is distal pancreatosplenectomy, which removes the body and tail of the pancreas along with the spleen. However, standard distal pancreatosplenectomy often yields inadequate oncological margins because the posterior dissection plane does not follow established anatomical boundaries that maximally clear retroperitoneal soft tissue.
The concept of Radical Antegrade Modular Pancreatosplenectomy (RAMPS) was introduced to address this limitation by defining an anatomically sound posterior dissection plane that achieves wider posterior margins, potentially improving R0 resection rates compared to standard approaches.
RAMPS proceeds in an antegrade (left-to-right) direction and divides the pancreatic neck first before dissecting the body and tail off the retroperitoneum. The key oncological principle is systematic clearance of the soft tissue posterior to the pancreas, including lymph nodes along the celiac axis and superior mesenteric artery.
Two variants are defined by the posterior dissection plane: anterior RAMPS dissects anterior to Gerota's fascia (the fascial envelope of the kidney), preserving the adrenal gland and kidney. Posterior RAMPS dissects posterior to Gerota's fascia, removing the left adrenal gland en bloc, used when the tumor is close to or involves the adrenal territory.
The minimally invasive approach to RAMPS - using either laparoscopic or robotic platforms - aims to replicate these oncological principles while reducing surgical morbidity, hospital length of stay, and recovery time compared to open surgery.
Laparoscopic RAMPS uses rigid straight instruments introduced through small port incisions. While technically demanding due to instrument limitations in angulation and dexterity, several series have demonstrated its feasibility with acceptable operative times and oncological outcomes in experienced hands.
The robotic platform (da Vinci surgical system) provides articulated instruments with seven degrees of freedom, three-dimensional high-definition vision, and tremor filtration. These advantages may facilitate the precise tissue dissection and vascular control required during RAMPS, particularly for the antegrade dissection phase near major vessels.
Both approaches require surgeon expertise and high-volume center experience. The learning curve for minimally invasive RAMPS is steep, and the current evidence base consists predominantly of retrospective single-institution series, limiting direct comparisons between platforms.
Multiple institutional series reviewed in this paper report R0 (margin-negative) resection rates of 70–100% with minimally invasive RAMPS, comparing favorably with historical open surgery benchmarks. High R0 rates are the principal surrogate for long-term survival benefit in PDAC surgery.
Reported operative times range widely (150–400 minutes) reflecting institutional learning curves, but blood loss and transfusion rates are generally lower with the minimally invasive approach versus open surgery. Morbidity rates, including postoperative pancreatic fistula, are comparable to open RAMPS.
The review identifies that patient selection is critical for optimal outcomes: best candidates are patients with pancreas-confined tumors, intact posterior fascia on preoperative imaging, and tumor location at least 1–2 cm from the celiac axis - criteria that currently limit applicability to a subset of all left-sided PDAC patients.
Achieving R0 resection is the single most important modifiable surgical factor for long-term survival in PDAC. RAMPS is designed specifically to maximize posterior margin clearance, which is the most common site of positive margins in standard distal pancreatosplenectomy.
Minimally invasive surgery provides well-established patient benefits including reduced postoperative pain, faster gastrointestinal recovery, shorter hospital stays, and earlier return to adjuvant chemotherapy - the last point being particularly important in PDAC where timely systemic therapy is associated with improved survival.
As robotic platforms become more widely available and surgeon training programs mature, minimally invasive RAMPS may become the standard of care for appropriately selected left-sided PDAC patients at high-volume centers, replacing open surgery as the default approach.
The evidence base for minimally invasive RAMPS is limited to retrospective, single-institution case series with heterogeneous patient selection criteria, operative technique details, and outcome reporting - making systematic meta-analysis difficult and conclusions tentative.
No randomized controlled trials comparing minimally invasive versus open RAMPS currently exist. Without level-one evidence, adoption decisions rest on surgeon experience and institutional preference rather than definitive efficacy data - a gap that prospective multicenter trials must address.
Future directions include standardized technique protocols, multi-institutional registries for systematic outcome tracking, investigation of RAMPS in the neoadjuvant chemotherapy setting (where tumor biology may differ), and integration of intraoperative fluorescence imaging for real-time margin assessment.